|
Title
|
|
|
|
Health 2020 en het innovative medicines initiative 2
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| In this article I will evaluate the Innovative Medicines Initiative 2 (IMI2), a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations. The guidelines of Health2020, the strategic health plan of the WHO European Region, will function as evaluation criteria. My aim is to show that the structural organization of the IMI2 leads to serious distortions in health research: there is too much attention for the health problems of the rich, and stakeholders such as patients and academics do not have enough opportunities to participate in constructive ways. I proceed as follows. I start with an overview of the issues identified in the literature as distortions in health research. Then I will show how Health2020 is designed to overcome these distortions. Given that the IMI2 is explicitly conceived to implement the guidelines of Health2020, I will use these as evaluation criteria. After discussing the main problems of the IMI2, I will then show how these distortions follow from the way in which the IMI2 is organized. In the last section I propose a possible solution: all stakeholders should be involved in the organization, rather than only politicians and industry. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Ethiek en maatschappij. - Gent, 1998, currens
| |
|
Publication
|
|
|
|
Gent
:
Academia Press
,
2016
| |
|
ISSN
|
|
|
|
1373-0975
| |
|
Volume/pages
|
|
|
|
18
:1
(2016)
, p. 45-70
| |
|
Full text (open access)
|
|
|
|
| |
|